SCHEMBL2555898

SCHEMBL2555898

OB(O)c1ccc(OCc2ccccc2F)c(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
ENPP2 Q13822 1/20 0.53
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
PKM P14618 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MRGPRX4 Q96LA9 4/20 0.46
CLCN2 P51788 1/20 0.45
PTGER1 P34995 3/20 0.44
LMNA P02545 3/20 0.44
ALDH1A1 P00352 2/20 0.44
USP2 O75604 1/20 0.44
MCL1 Q07820 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ESR1 P03372 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15330173 0.87 ENPP2 (0.57) MAPTSMN1; SMN2NPC1RAB9AENPP2
SCHEMBL2554921 0.83 TP53 (0.46) MAPTSMN1; SMN2NPC1RAB9AENPP2
SCHEMBL29952431 0.80 ENPP2 (0.66) MAPTSMN1; SMN2NPC1RAB9AENPP2
SCHEMBL8453 0.80 ENPP2 (0.66) MAPTSMN1; SMN2NPC1RAB9AENPP2
SCHEMBL3319862 0.78 MAPT (0.60) MAPTSMN1; SMN2NPC1RAB9AFNTA
SCHEMBL17858627 0.78 MAPT (0.60) MAPTSMN1; SMN2NPC1RAB9AFNTA
SCHEMBL15332082 0.78 LMNA (0.43) MAPTSMN1; SMN2NPC1RAB9APKM
SCHEMBL12260343 0.77 ENPP2 (0.63) SMN1; SMN2NPC1RAB9AENPP2MRGPRX4
SCHEMBL3761511 0.76 MAOB (0.59) SMN1; SMN2NPC1RAB9APKMTDP1
SCHEMBL19736986 0.76 RAB9A (0.57) MAPTSMN1; SMN2NPC1RAB9AFNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
CN-108368107-B Fused heterocyclic compounds as S1P modulators 艾伯维公司 2021-11-26 CN disclosed
US-10556907-B2 Fused heterocyclic compounds as S1P modulators AbbVie Deutschland GmbH & Co. KG (DE) 2020-02-11 US disclosed
US-20190327974-A1 SYNERGISTS FOR IMPROVED PESTICIDES THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 2019-10-31 US disclosed
US-20190327974-A1 SYNERGISTS FOR IMPROVED PESTICIDES THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 2019-10-31 US disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
EP-2558577-B1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION AS (DK) 2018-12-12 EP disclosed
WO-2018127928-A1 SYNERGISTS FOR IMPROVED PESTICIDES THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 2018-07-12 WO disclosed
WO-2018127928-A1 SYNERGISTS FOR IMPROVED PESTICIDES THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 2018-07-12 WO disclosed
US-20170057966-A1 FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS AbbVie Deutschland GmbH & Co. KG (DE) 2017-03-02 US disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 US disclosed
EP-2558577-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2013-02-20 EP disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190327974-A1 SYNERGISTS FOR IMPROVED PESTICIDES BCHE, DDT, DBF4 MAPT 2085/4885SMN1; SMN2 1786/4885NPC1 2275/4885
US-20170057966-A1 FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS S1PR1, S1PR2, S1PR3 MAPT 3696/4885SMN1; SMN2 3709/4885NPC1 167/4885
US-10556907-B2 Fused heterocyclic compounds as S1P modulators S1PR1, S1PR2, S1PR3 MAPT 3696/4885SMN1; SMN2 3709/4885NPC1 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.